345 related articles for article (PubMed ID: 33022763)
21. The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.
Yan Y; Ma J; Wang D; Lin D; Pang X; Wang S; Zhao Y; Shi L; Xue H; Pan Y; Zhang J; Wahlestedt C; Giles FJ; Chen Y; Gleave ME; Collins CC; Ye D; Wang Y; Huang H
EMBO Mol Med; 2019 Nov; 11(11):e10659. PubMed ID: 31559706
[TBL] [Abstract][Full Text] [Related]
22. Genetic Profiling of African American Patients With Prostatic Adenocarcinoma Metastatic to the Lymph Nodes: A Pilot Study.
Bidot S; Yin J; Zhou P; Zhang L; Deeb KK; Smith G; Hill CE; Xiu J; Bilen MA; Case KB; Tinsley M; Carthon B; Harik LR
Arch Pathol Lab Med; 2024 Mar; 148(3):310-317. PubMed ID: 37327205
[TBL] [Abstract][Full Text] [Related]
23. SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling.
Blattner M; Liu D; Robinson BD; Huang D; Poliakov A; Gao D; Nataraj S; Deonarine LD; Augello MA; Sailer V; Ponnala L; Ittmann M; Chinnaiyan AM; Sboner A; Chen Y; Rubin MA; Barbieri CE
Cancer Cell; 2017 Mar; 31(3):436-451. PubMed ID: 28292441
[TBL] [Abstract][Full Text] [Related]
24. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.
Geng C; He B; Xu L; Barbieri CE; Eedunuri VK; Chew SA; Zimmermann M; Bond R; Shou J; Li C; Blattner M; Lonard DM; Demichelis F; Coarfa C; Rubin MA; Zhou P; O'Malley BW; Mitsiades N
Proc Natl Acad Sci U S A; 2013 Apr; 110(17):6997-7002. PubMed ID: 23559371
[TBL] [Abstract][Full Text] [Related]
25. CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.
Augello MA; Liu D; Deonarine LD; Robinson BD; Huang D; Stelloo S; Blattner M; Doane AS; Wong EWP; Chen Y; Rubin MA; Beltran H; Elemento O; Bergman AM; Zwart W; Sboner A; Dephoure N; Barbieri CE
Cancer Cell; 2019 Apr; 35(4):603-617.e8. PubMed ID: 30930119
[TBL] [Abstract][Full Text] [Related]
26. SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.
Hernández-Llodrà S; Segalés L; Safont A; Juanpere N; Lorenzo M; Fumadó L; Rodríguez-Vida A; Cecchini L; Bellmunt J; Lloreta-Trull J
Prostate; 2019 Jul; 79(10):1156-1165. PubMed ID: 31090082
[TBL] [Abstract][Full Text] [Related]
27. Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer.
Geng C; Rajapakshe K; Shah SS; Shou J; Eedunuri VK; Foley C; Fiskus W; Rajendran M; Chew SA; Zimmermann M; Bond R; He B; Coarfa C; Mitsiades N
Cancer Res; 2014 Oct; 74(19):5631-43. PubMed ID: 25274033
[TBL] [Abstract][Full Text] [Related]
28. Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer.
Liu W; Lindberg J; Sui G; Luo J; Egevad L; Li T; Xie C; Wan M; Kim ST; Wang Z; Turner AR; Zhang Z; Feng J; Yan Y; Sun J; Bova GS; Ewing CM; Yan G; Gielzak M; Cramer SD; Vessella RL; Zheng SL; Grönberg H; Isaacs WB; Xu J
Oncogene; 2012 Aug; 31(35):3939-48. PubMed ID: 22139082
[TBL] [Abstract][Full Text] [Related]
29. Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer.
Rodrigues LU; Rider L; Nieto C; Romero L; Karimpour-Fard A; Loda M; Lucia MS; Wu M; Shi L; Cimic A; Sirintrapun SJ; Nolley R; Pac C; Chen H; Peehl DM; Xu J; Liu W; Costello JC; Cramer SD
Cancer Res; 2015 Mar; 75(6):1021-34. PubMed ID: 25770290
[TBL] [Abstract][Full Text] [Related]
30. Clinico-pathological significance of the molecular alterations of the SPOP gene in prostate cancer.
García-Flores M; Casanova-Salas I; Rubio-Briones J; Calatrava A; Domínguez-Escrig J; Rubio L; Ramírez-Backhaus M; Fernández-Serra A; García-Casado Z; López-Guerrero JA
Eur J Cancer; 2014 Nov; 50(17):2994-3002. PubMed ID: 25204806
[TBL] [Abstract][Full Text] [Related]
31. Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation.
Wu F; Dai X; Gan W; Wan L; Li M; Mitsiades N; Wei W; Ding Q; Zhang J
Cancer Lett; 2017 Jan; 385():207-214. PubMed ID: 27780719
[TBL] [Abstract][Full Text] [Related]
32. SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway.
Luo Z; Wang J; Zhu Y; Sun X; He C; Cai M; Ma J; Wang Y; Han S
Neoplasia; 2021 Oct; 23(10):1037-1047. PubMed ID: 34509929
[TBL] [Abstract][Full Text] [Related]
33. LRP5 competes for SPOP binding to enhance tumorigenesis mediated by Daxx and PD-L1 in prostate cancer.
Gan S; Qu F; Zhang X; Pan X; Xu D; Cui X; Hou J
Exp Cell Res; 2024 Jan; 434(1):113857. PubMed ID: 38008278
[TBL] [Abstract][Full Text] [Related]
34. Mutated SPOP E3 Ligase Promotes 17βHSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression.
Shi L; Yan Y; He Y; Yan B; Pan Y; Orme JJ; Zhang J; Xu W; Pang J; Huang H
Cancer Res; 2021 Jul; 81(13):3593-3606. PubMed ID: 33762355
[TBL] [Abstract][Full Text] [Related]
35. Destruction of DDIT3/CHOP protein by wild-type SPOP but not prostate cancer-associated mutants.
Zhang P; Gao K; Tang Y; Jin X; An J; Yu H; Wang H; Zhang Y; Wang D; Huang H; Yu L; Wang C
Hum Mutat; 2014 Sep; 35(9):1142-51. PubMed ID: 24990631
[TBL] [Abstract][Full Text] [Related]
36. Identification of speckle-type POZ protein somatic mutations in African American prostate cancer.
Buckles E; Qian C; Tadros A; Majumdar S; Cvitanovic J; Zabaleta J; Estrada J; Wilson J; Liu W
Asian J Androl; 2014; 16(6):829-32. PubMed ID: 24994784
[TBL] [Abstract][Full Text] [Related]
37. Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer.
Jin X; Wang J; Gao K; Zhang P; Yao L; Tang Y; Tang L; Ma J; Xiao J; Zhang E; Zhu J; Zhang B; Zhao SM; Li Y; Ren S; Huang H; Yu L; Wang C
PLoS Genet; 2017 Apr; 13(4):e1006748. PubMed ID: 28448495
[TBL] [Abstract][Full Text] [Related]
38.
Jillson LK; Rider LC; Rodrigues LU; Romero L; Karimpour-Fard A; Nieto C; Gillette C; Torkko K; Danis E; Smith EE; Nolley R; Peehl DM; Lucia MS; Costello JC; Cramer SD
Mol Cancer Res; 2021 Jul; 19(7):1123-1136. PubMed ID: 33846123
[TBL] [Abstract][Full Text] [Related]
39. Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness.
Huang S; Gulzar ZG; Salari K; Lapointe J; Brooks JD; Pollack JR
Oncogene; 2012 Sep; 31(37):4164-70. PubMed ID: 22179824
[TBL] [Abstract][Full Text] [Related]
40. Clinical and genomic features of SPOP-mutant prostate cancer.
Nakazawa M; Fang M; H Marshall C; Lotan TL; Isaacsson Velho P; Antonarakis ES
Prostate; 2022 Feb; 82(2):260-268. PubMed ID: 34783071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
